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Abstract
Background: In Down syndrome patients several metabolic abnormalities have been reported,
some involving the lipid metabolism. The level of LDL in plasma is the major determinant of the
risk of vascular disease. There appear to be no studies on the LDL receptor in Down syndrome
patients.
Methods:  Flow cytometric methods for measuring the LDL receptor in peripheral blood
mononuclear cells (PBMC) can identify patients with hypercholesterolemia. We applied this
method in 19 old patients with Down syndrome and 23 healthy controls.
Results: Down syndrome patients had high levels of triglycerides and low levels of HDL, and high
levels of CRP. We also found a down-regulation of LDL receptor expression.
Conclusions: Down syndrome patients show no increase in the frequency of cardiovascular
disease. The low incidence in cardiovascular disease despite the low level of HDL, high levels of
CRP and reduction of LDL receptor expression lead to the conclusion that either these are not
risk factors in these patients or that other risks factors – not yet identified – are considerably
lower.
Introduction
Several studies have discussed the psychological and intel-
lectual problems, immunological deficiencies, and early
aging of Down syndrome (DS) patients. Several metabolic
abnormalities have been reported, some involving the
lipid metabolism [1]. Apart from some contradictory
studies in the past, there are only few investigations of the
cholesterol fractions in DS patients. Therefore, it must be
concluded that the low prevalence of coronary artery dis-
ease in individuals with DS cannot be explained by their
cholesterol fractions. Mortality statistics of these patients
showed practically no deaths due to advanced atheroscle-
rosis [2], and similarly, pathological studies have detected
no increase in atherosclerosis – or even a complete
absence of atherosclerotic changes [3].
In children [4] and also adolescents [5] with DS low levels
of high-density lipoprotein (HDL) have been reported
and recently, we have learned much about the
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vasoprotective HDL cholesterol [6]. Anyway DS remains a
disease in which atherosclerosis is rare [7].
Measurements of LDL receptor expression are also neces-
sary to fully characterize the functional status of the low-
density lipoprotein (LDL) pathway which substantially
influences LDL levels in plasma, and its discovery consti-
tuted a major biological advance by providing molecular
explanations of hypercholesterolemia. The plasma LDL
level is the major determinant of the risk of vascular dis-
ease. We analyzed, also, C reactive protein (CRP), a cardi-
ovascular risk factors coded by genes lying on
Chromosome 21. Flow cytometric methods for measure-
ment of LDL receptor on peripheral blood mononuclear
cells (PBMC) may be used to identify patients with famil-
ial hypercholesterolemia [8]. Data in uremic patients sug-
gest that a defect in LDL receptor function in PBMC may
be due to a decrease in LDL receptor expression, which
could contribute to the aberrant lipoprotein metabolism
[9].
We therefore investigated LDL receptor expression on
uninduced PBMC, particularly T lymphocytes because
they express more LDL receptors than monocytes [10].
Since the progression of atherosclerosis is age-dependent,
LDL receptor interactions are important in lipid plaque
formation and T cells are present in early atherosclerotic
lesions, interacting with LDL through the LDL receptor
[11], we studied LDL expression on T lymphocytes in a
group of old patients with DS.
Methods
Blood samples were drawn from 19 old DS patients
(male, average age 55 years) and 23 healthy individuals
(male, average age 55 years) without dyslipidemia or any
family history of coronary heart disease, no smokers or
drunkers, with a Body Mass Index (BMI) < 25. Lipid meas-
urements are given in Table 1. Plasma C reactive protein
(CRP) concentration form DS and control was evaluated
by LANIA (Latex Agglutination Nephelometric Immu-
noassay) technique (Biolatex, Spain). Samples were
diluted 1:36 and results were calculated automatically by
IMMAGE system. The minimum detectable concentration
was 0.4 mg/dl.
None had been treated with lipid-lowering drugs before
blood sampling. This study was conducted in accordance
with the Declaration of Helsinki, 1975, amended in 1983.
Blood, collected in tubes containing EDTA, was cooled to
20°C and diluted 1:1 with Hank's buffered saline solution
(HBSS, Biochrome, Biospa, Milan, Italy). PBMCs were
prepared under sterile conditions, using Ficoll-Hypaque
(Pharmacia Biotech, Milan, Italy) and diluted blood was
layered in a centrifuge tube and centrifuged for 40 min at
400 g, 20°C. The interface containing the PBMCs was iso-
lated, and the cells were washed three times in HBSS and
resuspended in RPMI-1640 (Biochrome, Biospa, Milan,
Italy) with L-glutamine (290 mg/L), penicillin (100,000
U/L), streptomycin (100 mg/L) and 100 mL/L human
lipoprotein-deficient serum (HLPDS) to a final concentra-
tion of 106 cells/mL.
Tissue culture flasks were placed in ice-water for 60 min in
the dark to reduce cell adhesion. PBMCs were removed by
flushing with ice-cold HBSS (4°C) and washed twice in
ice-cold HBSS with 20 mL/L HLPDS. The cell number was
adjusted to 0.3 × 106 cells/mL, and 100-µL aliquots of cell
suspension were pipetted into polypropylene tubes and
placed in ice-water. Cells were incubated with 1.5 µg of
monoclonal mouse anti-human LDL receptor-specific
antibody, clone C7 (Amersham Life Science, Milan, Italy),
for 30 min in the dark at 4°C. After this the cells were
washed twice in ice-cold HBSS with 20 mL/L HLPDS, and
incubated with 3 µL of fluorescein isothiocyanate (FITC,
Dako Cytomation, Milan, Italy) for 30 min in the dark at
4°C. Cells were then incubated with 1 µL of R-phyco-
erythrin (RPE)-conjugated monoclonal antibody CD3-
RPE or IgG1isotype-RPE for T lymphocytes.
The flow cytometry measurements were done in a FACS-
can flow cytometer (Becton Dickinson, Milan, Italy)
equipped with a 15 mW, 488 nm, air-cooled argon laser
and linked to a computer with CellQuest software. For-
ward scatter (FSC) and side scatter (SSC) were adjusted to
exclude debris and dead cells. FITC emission was meas-
ured at 530 nm (FL1) and RPE emission at 585 nm (FL2);
compensation was set using FITC-conjugated C7 (C7
FITC)-labeled cells (FL2-FL1) and CD3-RPE-labeled cells
(FL1-FL2).
Means were compared by the unpaired t-test or one-way
analysis of variance (ANOVA). Data are presented as
means ± SD. Differences were considered statistically sig-
nificant at p < 0.05.
Results
Table 1 shows cholesterol fractions of DS patients and
healthy controls. DS total cholesterol and LDL did not dif-
fer from controls (p = 0.8 and p = 0.9 respectively). Blood
Table 1: Cholesterol fractions in old patients with Down 
syndrome and healthy subjects. Means ± SD.
Healthy subjects Down syndrome
Total cholesterol 150 ± 19.64 152 ± 28.79
Triglycerides 55.9 ± 21.46 104.5 ± 50.2
HDL-cholesterol 48.4 ± 10.5 40.6 ± 4.24
LDL-cholesterol 88.3 ± 17.2 89 ± 24.4Immunity & Ageing 2005, 2:3 http://www.immunityageing.com/content/2/1/3
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levels of CRP were higher in DS than in controls, as illus-
trated in Figure 1(Controls 1.3 ± 0.3; DS = 5.7 ± 4.6 mg/L,
p < 0.01). A regression analysis of data shows non rela-
tionship among CRP and cholesterol-related molecule
levels.
Triglycerides were higher, and HDL lower in DS patients
(p  < 0.01 and p  < 0.05). Our data also show that the
expression of LDL receptor on T lymphocytes was down-
regulated in DS patients (Table 2 and Figure 2).
Mean intensity fluorescence (MIF) of LDL receptor expres-
sion was significantly different in DS patients and healthy
controls (p < 0.0001) (Table 2).
Discussion
Patients with DS who reach adolescence nowadays have a
nearly normal life expectancy thanks to better medical
care. When they die at a later age, cardiovascular diseases
are less common than in the general population and they
have even been proposed as "an atheroma-free model"
Levels of C reactive protein (CRP) in plasma from children with DS and age matched controls Figure 1
Levels of C reactive protein (CRP) in plasma from children with DS and age matched controls. Data are presented as mean ± 
S.D.
Table 2: Mean fluorescence intensity (MFI, %) of LDL receptor 
expression in healthy subjects and old patients with Down 
syndrome. Means ± SD.
Healthy subjects Down syndrome
MFI (%) 196.76 ± 20.54 139.87 ± 13.32Immunity & Ageing 2005, 2:3 http://www.immunityageing.com/content/2/1/3
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[3]. Our results concerning cholesterol fractions suggest
that DS patients should have a cardiovascular disease risk,
if conclusions valid for the general population can be
transferred to this category of patients. Although serum
lipoprotein profiles cannot explain the lower prevalence
of cardiovascular disease in individuals with DS, our trig-
lyceride and HDL findings are in line with published fig-
ures. Similar findings were reported by other authors but
in young patients [4,5].
Multiple factors are responsible for atherosclerosis, such
as dietary habits but still the unexplained decline of LDL
receptor expression with aging contributes importantly to
borderline-high levels and cannot be ignored. For exam-
ple the loss of estrogen-stimulated LDL receptor synthesis
after menopause is an important contributor to elevated
cholesterol in postmenopausal women. In addition, sev-
eral genetic defects inherited singly appear to be causes of
moderate hypercholesterolemia [10,12]. Generally
defects of LDL receptor expression are associated with a
high risk of premature atherosclerosis. In the elderly LDL
receptor uptake is unexpectedly increased, and LDL recep-
tor regulation and expression and serum LDL composi-
tion seem abnormal. There may also be alterations to the
lipid metabolism of immune system cells during aging
[13].
In our series, a reduction in LDL receptor expression was
not correlated with high LDL serum levels or total choles-
terol. Moreover, lipophospholipid (LPC) is generated by
hydrolysis of phosphatidylcholine which is present in
LDL; LPC may promote the start of an immune response
and atherosclerosis may be the most extreme demonstra-
tion of this immune regulation pathway [14]. LPC may be
a potent super-regulator of T-cell activation by inflamma-
tion at sites of tissue damage and in the early stages of
atherosclerosis.
Interestingly, DS patients show no increase in their fre-
quency of cardiovascular disease.
These conditions may be explained by mild immune
defects in the syndrome, mainly involving macrophages
and/or TH1 lymphocytes responses [15]. Alternatively, a
over expression of atherosclerotic protective factors -yet
unknown- maight be present in Down syndrome. As we
reported earlier, the low incidence of cardiovascular dis-
ease in these patients and the high-risk factor of oxida-
tively modified LDL (oxLDL) [16] with – in this study –
the low level of HDL, high levels of CRP and reduction of
LDL receptor expression, lead to the conclusion that in
this group of "healthy old" DS subjects, classical
biochemical risk factors for atherosclerosis have been
detected but risks, probably, are considerably lower.
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